1. Academic Validation
  2. The Lasso Peptide Siamycin-I Targets Lipid II at the Gram-Positive Cell Surface

The Lasso Peptide Siamycin-I Targets Lipid II at the Gram-Positive Cell Surface

  • ACS Chem Biol. 2019 May 17;14(5):966-974. doi: 10.1021/acschembio.9b00157.
Stephanie Tan 1 Kevin C Ludwig 2 Anna Müller 2 3 Tanja Schneider 2 3 Justin R Nodwell 1
Affiliations

Affiliations

  • 1 Department of Biochemistry, MaRS Discovery District , University of Toronto , 661 University Avenue , Toronto , Ontario , Canada M5G 1M1.
  • 2 Institute for Pharmaceutical Microbiology , University of Bonn , Meckenheimer Allee 168 , 53115 Bonn , Germany.
  • 3 German Centre for Infection Research (DZIF) , partner site Bonn-Cologne , Bonn , Germany.
Abstract

Ribosomally synthesized post-translationally modified Peptides (RiPPs) are a diverse class of biologically active molecules produced by many environmental bacteria. While thousands of these compounds have been identified, mostly through genome mining, a relatively small number has been investigated at the molecular level. One less understood class of RiPPs is the lasso Peptides. These are 20-25 amino acid residue compounds bearing an N-terminal macrocyclic ring and a C-terminal tail that is threaded through the ring. We have carried out a detailed investigation on the mechanism of action of the siamycin-I lasso peptide. We demonstrate that siamycin-I interacts with lipid II, the central building block of the major cell wall component peptidoglycan, which is readily accessible on the outside of the cell. This interaction compromises cell wall biosynthesis in a manner that activates the liaI stress response. Additionally, resistance to siamycin-I can be brought about by mutations in the essential WalKR two-component system that causes thickening of the cell wall. Siamycin-I is the first lasso peptide that has been shown to inhibit cell wall biosynthesis.

Figures
Products